{"id":"NCT01999777","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU","officialTitle":"A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2013-12-03","resultsPosted":"2018-11-27","lastUpdate":"2019-10-10"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"USL261","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"USL261","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.","primaryOutcome":{"measure":"Number of Participants That Were Seizure-free","timeFrame":"6 hours","effectByArm":[{"arm":"USL261","deltaMin":17,"sd":null},{"arm":"Placebo","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1972"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":51,"countries":["United States","Australia","Austria","Belgium","Czechia","Germany","Lithuania","Spain"]},"refs":{"pmids":["33140403"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["Nasal discomfort","Product taste abnormal","Headache","Throat irritation","Nausea"]}}